CONMED Corp. 10-Q Summary: Quarter Ended September 29, 1995
Business Context and Reporting Period
CONMED Corporation, a developer, manufacturer, and marketer of disposable medical products and related devices, filed its quarterly report for the period ended September 29, 1995. The company is headquartered in Utica, New York. The reporting period reflects significant strategic expansion through the acquisition of Birtcher Medical Systems and The Master Medical Corporation.
Key Financial Metrics
| Metric | Three Months Ended Sept 29, 1995 | Nine Months Ended Sept 29, 1995 |
|---|---|---|
| Net Sales | $26,258,000 | $71,886,000 |
| Net Income | $2,889,000 | $7,547,000 |
| Earnings Per Share | $0.36 | $0.99 |
| Gross Margin | 47.7% | 47.2% |
| Operating Cash Flow | N/A | ($223,000) Used |
| Total Debt (Current + Long-term) | $33,840,000 | $33,840,000 |
| Cash and Equivalents | $1,602,000 | $1,602,000 |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 52.1% for the quarter and 36.5% for the nine-month period compared to 1994, driven primarily by the Birtcher and Master Medical acquisitions.
- Profitability: Net income for the quarter more than doubled to $2.889 million from $1.357 million. Gross margins improved to 47.7% (quarter) and 47.2% (nine months) due to manufacturing efficiencies and economies of scale.
- Expense Structure: While absolute selling and administrative expenses increased, they declined as a percentage of sales (25.1% vs. 29.6% for the quarter) due to the elimination of duplicate costs in acquired businesses.
- Balance Sheet: Total assets grew from $62.1 million to $118.1 million. Goodwill increased significantly from $13.1 million to $46.7 million due to acquisitions. Long-term debt rose from $6.9 million to $27.8 million to finance these transactions.
- Cash Flow: Operating cash flow turned negative ($223,000 used) for the nine months ended Sept 29, 1995, compared to $5.78 million provided in the prior year. This was caused by increased working capital requirements (receivables and inventories) and the payment of a $2.36 million patent litigation award.
Guidance, Outlook, and Risks
- Acquisition Activity: In October 1995, the company signed an agreement to acquire New Dimensions in Medicine, Inc. (NDM) for $32 million. To fund this, lenders committed to increasing the aggregate credit facility to $80 million.
- Liquidity: Management believes current cash resources and the expanded credit facility ($30 million term loan, $10 million revolving line) are sufficient for operations and capital expenditures.
- Legal Matters: A $2.1 million patent infringement award was affirmed by an appellate court. The company paid this award in the second quarter of 1995, and adequate provision was made in 1993.
- Pro Forma Results: On a pro forma basis assuming acquisitions occurred at the beginning of the period, nine-month net income would have been $8.456 million with EPS of $1.03.
Investor Verification Checklist
- Verify the integration progress and revenue contribution of the Birtcher and Master Medical acquisitions.
- Monitor the impact of the $32 million NDM acquisition on future leverage and cash flow.
- Review the status of the $80 million credit facility expansion and covenant compliance.
- Assess the sustainability of gross margins as the company scales operations post-acquisition.
- Confirm the resolution of any remaining patent litigation risks beyond the settled award.